Focused On-demand Library for tRNA N(3)-methylcytidine methyltransferase METTL2B

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q6P1Q9

UPID:
MET2B_HUMAN

ALTERNATIVE NAMES:
Methyltransferase-like protein 2B

ALTERNATIVE UPACC:
Q6P1Q9; B4DZ68; Q0IJ54; Q3B7J1

BACKGROUND:
The enzyme tRNA N(3)-methylcytidine methyltransferase METTL2B, alternatively named Methyltransferase-like protein 2B, is essential for the methylation of cytidine residues in tRNA molecules. This modification is critical for maintaining the proper structure and function of tRNA, thereby ensuring the fidelity of protein translation.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of tRNA N(3)-methylcytidine methyltransferase METTL2B holds promise for unveiling new therapeutic avenues. As a key player in the post-transcriptional modification landscape, targeting METTL2B could lead to innovative treatments for conditions linked to protein synthesis anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.